Prevalence of potential drug interactions in an Iranian general hospital

Indian Journal of Pharmaceutical Sciences

Volumn 74, Issue 1, 2012, Pages 75-79

  Sepehri, G ^a   Khazaelli, P ^b   Dahooie, F Arabpour ^c   Sepehri, E ^d   Dehghani, M R ^e  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Social Insurance Organization   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

General hospital; Iran; moderate; potential drug drug interactions; severe

Indexed keywords

ANTACID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM SPARING DIURETIC AGENT; QUINOLONE DERIVATIVE; THIAZIDE DIURETIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; DRUG INTERACTION; FEMALE; GENERAL HOSPITAL; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; PHARMACY; PRESCRIPTION; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE;

EID: 84870003433     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.102548     Document Type: Article

References (33)

1. Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993;27:832-40.
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5.
3. Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf 2007;16:641-51.
4. Jha AK, Kuperman GJ, Rittenberg E, Teich JM, Bates DW. Identifying hospital admissions due to adverse drug events using a computer-based monitor. Pharmacoepidemiol Drug Saf 2001;10:113-9.
5. Shad MU, Marsh C, Preskorn SH. The economic consequences of a drug-drug interaction. J Clin Psychopharmacol 2001;21:119-20.
6. Bobb A, Gleason K, Husch M, Feinglass J, Yarnold PR, Noskin GA. The epidemiology of prescribing errors: the potential impact of computerized prescriber order entry. Arch Intern Med 2004;164:785-92.
7. Doubova SV, Reyes-Morales H, Torres-Arreola Ldel P, Suarez-Ortega M. Potential drug-drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City. BMC Health Serv Res 2007;7:147.
8. Janchawee B, Owatranporn T, Mahatthanatrakul W, Chongsuvivatwong V. Clinical drug interactions in outpatients of a university hospital in Thailand. J Clin Pharm Ther 2005;30:583-90.
9. Kaushal R, Bates DW, Landrigan C, McKenna KJ, Clapp MD, Federico F, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001;285:2114-20.
10. Klarin I, Wimo A, Fastbom J. The association of inappropriate drug use with hospitalisation and mortality: a population-based study of the very old. Drugs Aging 2005;22:69-82.
11. McCabe BJ. Prevention of food-drug interactions with special emphasis on older adults. Curr Opin Clin Nutr Metab Care 2004;7:21-6.
12. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002;36:1331-6.
13. Peterson JF, Bates DW. Preventable medication errors: identifying and eliminating serious drug interactions. J Am Pharm Assoc (Wash) 2001;41:159-60.
14. Becker ML, Caspers PW, Kallewaard M, Bruinink RJ, Kylstra NB, Heisterkamp S, et al. Determinants of potential drug-drug interaction associated dispensing in community pharmacies in the Netherlands. Pharm World Sci 2007;29:51-7.
15. Cruciol-Souza JM, Thomson JC. A pharmacoepidemiologic study of drug interactions in a Brazilian teaching hospital. Clinics 2006;61:515-20.
16. Heininger-Rothbucher D, Bischinger S, Ulmer H, Pechlaner C, Speer G, Wiedermann CJ. Incidence and risk of potential adverse drug interactions in the emergency room. Resuscitation 2001;49:283-8.
17. Janchawee B, Wongpoowarak W, Owatranporn T, Chongsuvivatwong V. Pharmacoepidemiologic study of potential drug interactions in outpatients of a university hospital in Thailand. J Clin Pharm Ther 2005;30:13-20.
18. Koh TW. Risk of torsades de pointes from oral erythromycin with concomitant carbimazole (methimazole) administration. Pacing Clin Electrophysiol 2001;24:1575-6.
19. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. JAMA 1990;264:2788-90.
20. Wynn RL. Erythromycin and ketoconazole (Nizoral) associated with terfenadine (Seldane)-induced ventricular arrhythmias. Gen Dent 1993;41:27-9.
21. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996;335:290-1.
22. Bjorkman IK, Fastbom J, Schmidt IK, Bernsten CB. Drug-drug interactions in the elderly. Ann Pharmacother 2002;36:1675-81.
23. Cruciol-Souza JM, Thomson JC. Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci 2006;9:427-33.
24. Merlo J, Liedholm H, Lindblad U, Bjorck-Linne A, Falt J, Lindberg G, et al. Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: Cross sectional study. BMJ 2001;323:427-8.
25. Costa AJ. Potential drug interactions in an ambulatory geriatric population. Fam Pract 1991;8:234-6.
26. Lindblad CI, Artz MB, Pieper CF, Sloane RJ, Hajjar ER, Ruby CM, et al. Potential drug-disease interactions in frail, hospitalized elderly veterans. Ann Pharmacother 2005;39:412-7.
27. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drugdrug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003;289:1652-8.
28. Weih M, Bachmeier C, Degirmenci U, Sojer R, Kreil S, Thurauf N, et al. Assessment of Possible Drug-Drug Interactions in Psychopharmacotherapy after Hospital Discharge using an Interactive Database. Fortschr Neurol Psychiatr 2011:79: 92-6.
29. Magro L, Conforti A, Del Zotti F, Leone R, Iorio ML, Meneghelli I, et al. Identification of severe potential drug-drug interactions using an Italian general-practitioner database. Eur J Clin Pharmacol 2008;64:303-9.
30. Kohler GI, Bode-Boger SM, Busse R, Hoopmann M, Welte T, Boger RH. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000;38:504-13.
31. Sepcic K, Perkovic O, Turel I, Sepcic J. [Adverse effects and interactions of fluoroquinolones]. Lijec Vjesn 2009;131:74-80.
32. Navare HA, Frye RF, Cooper-Dehoff RM, Shuster JJ, Hall K, Schmidt SO, et al. Atenolol exposure and risk for development of adverse metabolic effects: a pilot study. Pharmacotherapy 2010;30:872-8.
33. Ansari J. Drug interaction and pharmacist. J Young Pharm 2010;2:326-31.